CN101190936A - Compound with antiviral activity - Google Patents
Compound with antiviral activity Download PDFInfo
- Publication number
- CN101190936A CN101190936A CNA2006100706091A CN200610070609A CN101190936A CN 101190936 A CN101190936 A CN 101190936A CN A2006100706091 A CNA2006100706091 A CN A2006100706091A CN 200610070609 A CN200610070609 A CN 200610070609A CN 101190936 A CN101190936 A CN 101190936A
- Authority
- CN
- China
- Prior art keywords
- base
- group
- butyl
- propenyl
- sec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention pertains to the technical field of medicine, relating to new compounds, which have the activity of antivirus, etc., or stereoisomer thereof, the preparation methods of the compounds or the stereoisomer thereof, medical compositions which comprise the compounds or the stereoisomer thereof as necessary active ingredients, the application of the compounds or the stereoisomer thereof in the preparation of medicine to cure and/or prevent viral infection and hepatopathy. The compounds or the stereoisomer thereof of the invention have the prominent functions of antivirus, in particular to hepatitis B virus and human immunodeficiency virus, and have prominent activity to resist acute and chronic hepatic injury at the same time.
Description
1, technical field
The present invention relates to have new compound or its steric isomer of antiviral isoreactivity, the preparation method of these compounds or its steric isomer, contain these compounds or its steric isomer pharmaceutical composition as essential activeconstituents, and these compounds or its steric isomer treat and/or prevent application in the medicine of viral infection and hepatic diseases in preparation, belongs to medical technical field.
2, background technology
Virus infection causes multiple disease, serious harm human beings'health and life.According to incompletely statistics, about 60% epidemic infectious diseases is caused by virus.Having found has pathogenic virus to reach kind more than 1200 to the people, and wherein sickness rate is the highest, hazardness is maximum is the chronic hepatitis B (CHB) that acquired immune deficiency syndrome (AIDS) (AIDS) due to the human immunodeficiency virus of finding the eighties in 20th century (HIV) and hepatitis B virus (HBV) cause.
Since early 1980s was found the first AIDS case, AIDS walked crosswise the whole world, serious threat human beings'health and existence, to 2003 the end of the year whole world have more than 4,000 ten thousand people to suffer from AIDS or belong to the virus carrier, about 3,000,000 people are because AIDS death.AIDS has become the human the fourth-largest cause of death.China Ministry of Health announced Chinese HIV the infected 840,000 in 2003, and AIDS patient 80,000, dead nearly 200,000 people.China HIV virus infection person is just with 30%～40% speed increase, and AIDS has become one of major disease of China's emphasis control.
According to World Health Organization's statistics, it is chronic hepatitis patient or hepatitis B virus (HBV) carrier that the whole world in 2000 has 3.5 hundred million people approximately, has every year more than 100 ten thousand people to die from and hepatitis, liver cirrhosis, liver cancer diseases associated.China is the district occurred frequently of viral hepatitis, and the HBV carrier has 1.2 hundred million people, accounts for 1/3 of world HBV number of the infected, and wherein chronic hepatitis B patients is about 3,000 ten thousand, and about 10%～20% can develop into liver cirrhosis, and 1%～5% can develop into liver cancer.Alpha-interferon and lamivudine are the internationally recognized curative effect medicine of hepatitis B virus resisting preferably at present, but there is patient more than half after treating, not heal for a long time, immunoregulation druge also is difficult to remove virus, cause virus in liver cell, to duplicate activity for a long time, hepatic tissue continues infringement, liver function persistent anomaly.Therefore protect liver cell, improving liver function is the important requisite aspect of treatment chronic hepatitis B (CHB).
3, summary of the invention
Acquired immune deficiency syndrome (AIDS) due to the HIV and the chronic hepatitis B due to the HBV have become the disease of serious harm human beings'health and life, in order to improve AIDS and CHB patient's life quality, effectively treat AIDS and CHB, our pharmaceuticals researcher has carried out many explorations, is devoted to seek new antiviral.
We study and have synthesized a large amount of new compounds, find that by the pharmacological experiment study screening new compound of the present invention has significant antiviral activity.
Technical scheme of the present invention is as follows:
The invention provides suc as formula the compound shown in (I) or its steric isomer:
Wherein,
Y is guanine-9-base, VITAMIN B4-9-base, 2,6-diaminopurine-9-base, 2-aminopurine-9-base or its 1-denitrification is assorted, the 3-denitrification is assorted or the 8-aza analogues perhaps removes aza analogues for cytosine(Cyt)-1-base, uridylic-1-base, thymus pyrimidine-1-base or its 3-;
R
1Be H, F, Cl, Br or I;
R
2Be H, perhaps 1～3 molecule glucose base, glucal acidic group, arabopyranose base, arbinofuranose base, rhamanopyranosyl, ribosyl, deoxyribosyl, lactose base, galactosyl, galacturonic acidic group, malt-base, mannose group, xylosyl;
R
3, R
4, R
5Independently hydroxyl, perhaps replacement or unsubstituted C respectively do for oneself
1-6Alkyl, thiazolinyl or the alkane hydroxyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, methylol, hydroxyethyl, hydroxypropyl, hydroxyl butyl; Wherein, described substituting group can be hydroxyl, amino, nitro, fluorine, chlorine, bromine, iodine, C
1-6The alkyl or alkenyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, C
6-10Aryl, be selected from phenyl, Alpha-Naphthyl or betanaphthyl, C
1-4The alkyl amido of straight or branched is selected from formamido group, kharophen, propionamido, butyrylamino, C
1-4The alkoxy carbonyl of straight or branched is selected from methoxycarbonyl, ethoxy carbonyl, propoxycarbonyl, isopropoxy carbonyl, butoxy carbonyl, isobutoxy carbonyl;
R
6Replace or unsubstituted C
1-6The alkyl or alkenyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, methylol, hydroxyethyl, hydroxypropyl, hydroxyl butyl; Wherein, described substituting group can be hydroxyl, amino, and nitro, halogen is selected from fluorine, chlorine, bromine, iodine, C
1-4The alkyl or alkenyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl.
Preferred compound is:
Y is guanine-9-base, VITAMIN B4-9-base, 2,6-diaminopurine-9-base, 2-aminopurine-9-base, cytosine(Cyt)-1-base, uridylic-1-base or thymus pyrimidine-1-base;
R
1Be H, F, Cl or Br;
R
2Be H, perhaps 1～3 molecule glucose base, glucal acidic group, arabopyranose base, arbinofuranose base, rhamanopyranosyl;
R
3, R
4, R
5Independently hydroxyl, perhaps replacement or unsubstituted C respectively do for oneself
1-4Alkyl, thiazolinyl or the alkane hydroxyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl, methylol, hydroxyethyl, hydroxypropyl, hydroxyl butyl; Described substituting group is same as above;
R
6For replacing or unsubstituted C
1-4The alkyl or alkenyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl; Described substituting group is same as above.
Further preferred compound is:
Y is guanine-9-base, VITAMIN B4-9-base, cytosine(Cyt)-1-base, uridylic-1-base or thymus pyrimidine-1-base;
R
1Be H, F or Cl;
R
2Be H, perhaps 1～3 molecule glucose base, glucal acidic group, arabopyranose base, arbinofuranose base;
R
3, R
4, R
5Independently hydroxyl, perhaps replacement or unsubstituted C respectively do for oneself
1-3Alkyl, thiazolinyl or the alkane hydroxyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, methylol, hydroxyethyl, hydroxypropyl; Described substituting group is same as above;
R
6For replacing or unsubstituted C
1-4The alkyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl; Described substituting group is same as above.
Further preferred compound is:
Y is guanine-9-base, VITAMIN B4-9-base or cytosine(Cyt)-1-base;
R
1Be H, F or Cl;
R
2Be H ,-β-D-glucosyl group ,-the alpha-D-glucose base or-β-D-glucal acidic group-alpha-D-glucose aldehydic acid base;
R
3Be methyl or methylol;
R
4Be methyl or methylol;
R
5Be methyl, hydroxyl or methylol;
R
6Be methyl, ethyl, propyl group or sec.-propyl.
Most preferred is:
2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as compd A), structural formula is as follows:
2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as compd B), structural formula is as follows:
2-(VITAMIN B4-9-yl) ethyl 3-(β base-2-O-β-D-glucopyranoside aldehydic acid base-α-D-glucopyranoside aldehydic acid)-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as Compound C), structural formula is as follows:
2-(VITAMIN B4-9-yl) propyl group 3-(β base-2-O-β-D-glucopyranoside aldehydic acid base-α-D-glucopyranoside aldehydic acid)-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as Compound D), structural formula is as follows:
2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as compd E), structural formula is as follows:
2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as compound F 17-hydroxy-corticosterone), structural formula is as follows:
2-(VITAMIN B4-9-yl) ethyl 3-(β base-2-O-β-D-glucopyranoside aldehydic acid base-α-D-glucopyranoside aldehydic acid)-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as compound G), structural formula is as follows:
2-(VITAMIN B4-9-yl) propyl group 3-(β base-2-O-β-D-glucopyranoside aldehydic acid base-α-D-glucopyranoside aldehydic acid)-18 β, 20 β-volatile oil-12-olefin(e) acid ester (hereinafter to be referred as compound H), structural formula is as follows:
Contain a plurality of chiral carbon in the structure of above-claimed cpd, the group on the chiral carbon can be α or beta comfiguration, so multiple steric isomer can be arranged, especially its α-H of 18 can become β-H, shown in (II), and wherein X, Y, R
1, R
2, R
3, R
4, R
5, R
6Implication same as above.
The compounds of this invention can be by following prepared, but is not limited only to following technology:
In the dry reaction bottle, add compound shown in acetonitrile, the structural formula (III) or its isomer (wherein X, R
1, R
2, R
3, R
4, R
5Implication same as above), add Dimethylamino pyridine (DMAP) then, after the stirring and dissolving, add dicyclohexylcarbodiimide (DCC), heat up and stir, slowly add compound shown in the structural formula (IV) (wherein Y, R then
6Implication same as above), dropwise continuous stirring reaction, cross the dicyclohexylurea (DCU) filter out generation, reclaim solvent, residuum is used ethyl acetate extraction after adding an amount of frozen water, the organic layer drying, reclaim solvent, the dehydrated alcohol recrystallization gets The compounds of this invention or its isomer.
The further claimed above-claimed cpd of the present invention or its steric isomer treat and/or prevent application in the medicine of viral infection in preparation.The compounds of this invention or its steric isomer have significant antiviral activity.Pharmacological evaluation shows that The compounds of this invention has remarkable restraining effect to duck DHBV virus, and no tangible rebound phenomenon after the drug withdrawal; 5% serum is cultivated in the MT-4 cell behind the mouse administration The compounds of this invention has remarkable restraining effect to HIV-1 IIIB P24 antigen.Experimental result shows that The compounds of this invention all has remarkable restraining effect to HBV and HIV, has significant antiviral activity.
The further claimed above-claimed cpd of the present invention or its steric isomer treat and/or prevent application in the medicine of hepatic diseases in preparation.The compounds of this invention or its steric isomer have significant liver-protecting activity.Pharmacological evaluation shows, The compounds of this invention can significantly reduce tetracol phenixin and cause gpt (ALT) and glutamic-oxal(o)acetic transaminase (AST) level in the mice serum behind the acute liver damage, and alleviates liver tissue injury, to CCl
4The poisoning mice liver injury has remarkable provide protection; The compounds of this invention can significantly reduce tetracol phenixin and cause ALT, AST in the chronic hepatic injury rat blood serum and the level of hyaluronic acid (HA), significantly reduce the content of oxyproline (Hyp) in the hepatic tissue, reduce the hepatic disease degree, can significantly improve liver function, alleviate hepatic fibrosis.Experimental result shows that The compounds of this invention has remarkable provide protection to acute and chronic hepatic injury.
The present invention also further claimed above-claimed cpd or its steric isomer of comprising as the essential activeconstituents and the pharmaceutical composition of pharmaceutically acceptable carrier, for clinically or pharmaceutically acceptable arbitrary formulation; Can parenteral, mode such as oral, percutaneous dosing is applied to the patient who needs this treatment, is preferably oral preparations or injection.Containing of the present invention compound or its steric isomer (in The compounds of this invention or its steric isomer) 2mg～2g of physiology significant quantity in the aforementioned pharmaceutical compositions, for example can be 2mg, 5mg, 6mg, 7.5mg, 10mg, 12mg, 13mg, 15mg, 20mg, 23mg, 25mg, 28mg, 30mg, 35mg, 37mg, 40mg, 45mg, 47mg, 50mg, 55mg, 57mg, 60mg, 70mg, 80mg, 85mg, 90mg, 95mg, 100mg, 110mg, 120mg, 130mg, 140mg, 150mg, 160mg, 170mg, 180mg, 190mg, 0.2g, 0.235g, 0.25g, 0.3g, 0.33g, 0.35g, 0.4g, 0.45g, 0.47g, 0.5g, 0.52g, 0.55g, 0.6g, 0.65g, 0.7g, 0.75g, 0.8g, 0.85g, 0.9g, 0.95g, 1g, 2g etc.
When being used for administered parenterally, can be made into injection.Injection means the intravital solution of confession injection, emulsion or the suspension that medicine is made and supplies to face with preceding preparation or be diluted to solution or the sterile preparation of the powder of suspension or strong solution that injection can be divided into injection liquid, injectable sterile powder and concentrated solution for injection.Injection liquid means that the confession that medicine is made is injected into sterile solution type injection liquid, emulsion-type injection liquid or the suspension type injection liquid of using in the body, can be used for intramuscularly, intravenous injection, intravenous drip etc.; Its specification has 1ml, 2ml, 5ml, 10ml, 20ml, 50ml, 100ml, 200ml, 250ml, 500ml etc., and wherein large volume (generally the being not less than 100ml) injection liquid of using for intravenous drip also claims intravenous infusion.Injectable sterile powder means that confession that medicine is made is faced with the suitable sterile solution of preceding usefulness and is mixed with settled solution or the evenly sterilized powder or the aseptic block of suspension, available suitable solvent for injection preparation back injection, also available intravenous infusion preparation posterior vein instils; Sterilized powder makes with solvent crystallization, spray-drying process or freeze-drying etc.Concentrated solution for injection means that confession that medicine is made faces the aseptic strong solution of using for intravenous drip with preceding dilution.
When making injection, can adopt the ordinary method production in the existing pharmacy field, optional use solvent or non-aqueous solvent.The most frequently used aqueous solvent is a water for injection, also available 0.9% sodium chloride solution or other suitable aqueous solution; Non-aqueous solvent commonly used is a vegetables oil, is mainly the injection soybean oil, and other also have the aqueous solution of ethanol, propylene glycol, polyoxyethylene glycol etc.During the preparation injection, can not add additives, also can add suitable additives, as osmotic pressure regulator, pH value conditioning agent, solubilizing agent, weighting agent, oxidation inhibitor, fungistat, emulsifying agent, suspending agent etc. according to the character of medicine.Osmotic pressure regulator commonly used comprises sodium-chlor, glucose, Repone K, magnesium chloride, calcium chloride, sorbyl alcohol etc., preferred sodium-chlor or glucose; PH value conditioning agent commonly used comprises acetic acid-sodium-acetate, lactic acid, Citric Acid-Sodium Citrate, sodium bicarbonate-yellow soda ash etc.; Solubilizing agent commonly used comprises Polysorbate 80, propylene glycol, Yelkin TTS, polyoxyethylenated castor oil etc.; Weighting agent commonly used comprises lactose, N.F,USP MANNITOL, sorbyl alcohol, dextran etc.; Oxidation inhibitor commonly used has S-WAT, sodium bisulfite, Sodium Pyrosulfite etc.; Fungistat commonly used is phenol, cresols, trichloro-butyl alcohol etc.Injection container commonly used has glass ampoule, vial, plastic ampoule, Plastic Bottle etc.
Be used for when oral, can be made into conventional solid preparation, as tablet, capsule, pill, granule etc.; Also can be made into oral liquid, as oral solution, oral suspensions, syrup etc.Tablet means disk shape or the special-shaped flaky solid preparation that medicine and the auxiliary materials and mixing compacting that suits form, based on oral ordinary tablet, other has lozenge, Sublingual tablet, mouth paster, chewable tablet, dispersible tablet, fuse, effervescent tablet, slow releasing tablet, controlled release tablet and enteric coated tablet etc.Capsule means medicine or is added with the auxiliary material filling in Capsules or be sealed in solid preparation in the soft capsule material, according to its dissolving and release characteristics, can be divided into hard capsule (being commonly referred to as capsule), soft capsule (capsule and pill), slow releasing capsule, controlled release capsule and enteric coated capsule etc.Pill means medicine and suitable auxiliary material uniform mixing, and the spherical or near-spherical solid preparation so that proper method is made comprises dripping pill, sugar-pill, piller etc.Granule means that medicine and suitable auxiliary material make the dried particles shape preparation with certain particle size, can be divided into soluble particles (being commonly referred to as particle), mix suspension grain, effervescent granule, enteric coated particles, slow-releasing granules and controlled release granule etc.Oral solution means that medicine dissolution makes for oral clarified liq preparation in suitable solvent.Oral suspensions means the insoluble solid pharmaceutical, is dispersed in the liquid medium, makes for oral suspension body preparation, also comprises dry suspensoid or dense suspension.Syrup means the dense aqueous sucrose solution that contains medicine.
When making oral preparations, can add suitable weighting agent, tackiness agent, disintegrating agent, lubricant etc.Weighting agent commonly used comprises starch, Icing Sugar, calcium phosphate, calcium sulfate two water things, dextrin, Microcrystalline Cellulose, lactose, pregelatinized Starch, N.F,USP MANNITOL etc.; Typical binders comprises Xylo-Mucine, PVP-K30, hydroxypropylcellulose, starch slurry, methylcellulose gum, ethyl cellulose, hypromellose, gelling starch etc.; Disintegrating agent commonly used comprises dry starch, polyvinylpolypyrrolidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose etc.; Conventional lubricants comprises Magnesium Stearate, talcum powder, sodium lauryl sulphate, micropowder silica gel etc.
The compounds of this invention or its steric isomer compared with prior art have the following advantages:
(1) provides new compound first with remarkable antiviral isoreactivity, especially 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester, 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester, 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester, 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester have enriched the clinical application kind.
(2) pharmacological evaluation shows, The compounds of this invention has remarkable restraining effect to duck DHBV virus, and no tangible rebound phenomenon after the drug withdrawal, 5% serum is cultivated in the MT-4 cell behind the mouse administration The compounds of this invention has remarkable restraining effect to HIV-1 IIIB P24 antigen, and significant antivirus action is arranged.
(3) pharmacological evaluation shows, The compounds of this invention all has remarkable provide protection to tetracol phenixin induced mice acute liver damage and rat chronic liver injury, and the effect that significantly resists acute and chronic hepatic injury is arranged.
(4) The compounds of this invention has significant anti-HBV and HIV activity, and has significant liver-protecting activity, has the good clinical using value.
Below routine by experiment beneficial effect of further setting forth The compounds of this invention.The compounds of this invention has following beneficial effect, but this should be interpreted as that The compounds of this invention only has following beneficial effect.
Replace 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-11-oxo-18 β with compd A in the following experimental example, 20 β-volatile oil-12-olefin(e) acid ester, compd B replaces 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester, compd E replaces 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester, compound F 17-hydroxy-corticosterone replaces 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester.
The effect of the anti-duck hepatitis B virus of experimental example 1 The compounds of this invention (DHBV)
Animal subject: 1 age in days Beijing duck, male and female dual-purpose.
Trial-product: physiological saline: commercial;
Compd A capsule: 13mg;
Compd B capsule: 13mg;
Compd E capsule: 13mg;
Compound F 17-hydroxy-corticosterone capsule: 13mg.
Dosage: see Table 1, model group gives sodium chloride injection.
Experimental technique: 1 age in days Beijing duck abdominal injection DHBV-DNA positive-virus serum, every 0.1ml, inoculated for 1 week after, respectively external jugular vein blood drawing detects to filter out through dot hybridization and infects positive duck, raise to 2 ages in week as laboratory animal.50 of positive ducks with infecting successfully are divided into 5 groups at random, 10 every group, are respectively model group and each administration group.Infect back beginning in the 13rd day, model group is irritated stomach and give physiological saline 20ml/kg every day, and each administration group is diluted to desired concn gastric infusion 20ml/kg by dosage shown in the table 1 with physiological saline, and every day 1 time, continuous 10 days, drug withdrawal was observed 3 days.Respectively at before the administration, administration 5 days, administration 10 days, drug withdrawal external jugular vein blood drawing in 3 days, separation of serum is to be checked in-20 ℃ of preservations.Adopt spot hybridization to measure the variation of serum DHBV-DNA, the spot value is volume (volume=intensity * mm
2).
Experimental result: see Table 1.Duck serum DHBV-DNA titre did not have obvious reduction after model group gave physiological saline, compd A, compd B, compd E, 5 days, 10 days duck serum DHBV of each administration group administration of compound F 17-hydroxy-corticosterone DNA titre all extremely significantly reduce (p＜0.01), and the DHBV-DNA level is respectively organized in drug withdrawal after 3 days do not have obvious rising.
The comparison of duck serum DHBV-DNA level before and after the table 1 administration The compounds of this invention (X ± S, n=10)
With compare before the administration:
*P＜0.01.
Study human hepatitis B pathogeny, virus replication and screen effective medicine as the hepatitis B animal model with the DHBV infected duck, generally acknowledged by Chinese scholars.1～3 age in days duckling infects DHBV can keep long-term viremia and not have the tangible phenomenon of turning out cloudy naturally, and we use 1 age in days duckling and set up the research that the duck hepatitis-B animal model carries out The compounds of this invention hepatitis B virus resisting curative effect through the method for abdominal cavity infection DHBV.Experimental result shows that The compounds of this invention has remarkable restraining effect to duck DHBV virus, and no tangible rebound phenomenon after the drug withdrawal, shows that The compounds of this invention has significant curative effect to viral hepatitis.
Experimental example 2 The compounds of this invention cause the provide protection of chmice acute liver injury to tetracol phenixin
Animal subject: healthy mice, 60, body weight 20～25g, the male and female dual-purpose is divided into 6 groups at random, 10 every group.
Trial-product: sodium chloride injection: 250ml: 2.25g, Shangdong Changfu Jiejing Pharmaceutical Industry Co., Ltd.;
Compd A injection liquid: 5ml: 110mg;
Compd B injection liquid: 5ml: 110mg;
Compd E injection liquid: 5ml: 110mg;
Compound F 17-hydroxy-corticosterone injection liquid: 5ml: 110mg.
Dosage: see Table 2, normal control group and model group give sodium chloride injection.
Experimental technique: mouse is divided into normal control group, model group and each administration group, 10 every group at random by body weight.Normal control group and model group abdominal injection sodium chloride injection 20ml/kg, each administration group is diluted to desired concn intraperitoneal injection 20ml/kg by dosage shown in the table 2 with sodium chloride injection, every day 1 time, continuous 7 days.Behind the last administration 2h, normal control group abdominal injection sweet oil 10ml/kg, all the other respectively organize equal abdominal injection 0.1% tetracol phenixin (CCl
4) olive oil solution 10ml/kg.The sacrificed by decapitation animal is got serum behind the 20h, measures serum glutamic pyruvic transminase (ALT) and glutamic-oxal(o)acetic transaminase (AST) level.After broken end was got blood, hepatic tissue was done the routine pathology histological examination.
Experimental result: see Table 2.Compare with the normal control group, model group mice serum ALT and AST level sharply raise (p＜0.01), and histopathologic examination finds that hepatic tissue is obviously impaired, and necrosis occurs, and the modeling success is described.Compare with model group, compd A, compd B, compd E, each administration group mice serum ALT of compound F 17-hydroxy-corticosterone and AST water mean pole significantly reduce (p＜0.01), and liver tissue injury significantly alleviates.
Table 2 The compounds of this invention is to CCl
4The influence of liver injury mice serum ALT and AST level (X ± S, n=10)
Compare with the normal control group:
##P＜0.01; Compare with model group:
*P＜0.01.
Conclusion: peroxidatic reaction of lipid mainly takes place after entering body in tetracol phenixin in hepatomicrosome, cause the infringement of liver plasma membrane 26S Proteasome Structure and Function, and cell interior ALT, AST are overflowed, and causes the active rising of ALT in the blood, AST.The hepatic injury zone is big more, and ALT, AST activity are high more.Result of study shows that The compounds of this invention can significantly reduce ALT and the AST level in the mice serum, alleviates liver tissue injury, to CCl
4The poisoning mice liver injury has remarkable provide protection, and remarkable anti-acute liver damage effect is arranged.
Experimental example 3 The compounds of this invention cause the effect of rat chronic liver injury to tetracol phenixin
Animal subject: healthy rat, 60, body weight 200～220g, the male and female dual-purpose is divided into 6 groups at random, 10 every group.
Trial-product: physiological saline: commercial;
Compd A capsule: 110mg
Compd B capsule: 110mg;
Compd E capsule: 110mg;
Compound F 17-hydroxy-corticosterone capsule: 110mg.
Dosage: see Table 3, normal control group and model group give physiological saline.
Experimental technique: rat is divided into normal control group, model group and each administration group, 10 every group at random by body weight.Except that the normal control group, all animal abdominal part hypodermic 25%CCl
4Olive fluid 2ml/kg, normal control group injection equivalent sweet oil, 2 times weekly, continuous 13 weeks.Each is organized in giving CCl
4The 5th week was played administration, and normal control group and model group are irritated the stomach group and given physiological saline 20ml/kg, and each administration group is diluted to desired concn gastric infusion 20ml/kg by dosage shown in the table 3 with physiological saline, and every day 1 time is continuously to the 13rd week.Behind the last administration 24h, put to death animal, (hyaluronic acid, HA) content separate left lobe of liver tissue test oxyproline (hydroxyproline, Hyp) content and pathology section examination from determination of serum Serum ALT, AST, hyaluronic acid to get blood system.
Experimental result: (1) is to the influence of Serum ALT and AST level: the results are shown in Table 3.Compare with the normal control group, model group rat blood serum transaminase level all extremely significantly raises (p＜0.01), and the ALT level is about 60 times of normal control group, and the AST level is about 29 times of normal control group.Compare with model group, ALT and AST water mean pole significantly reduce (p＜0.01) in compd A, compd B, compd E, each administration group rat blood serum of compound F 17-hydroxy-corticosterone.
(2) to the influence of serum HA and hepatic tissue Hyp content: the results are shown in Table 3.Compare model group rat blood serum HA content extremely significantly raise (p＜0.01) with the normal control group; Hyp content extremely significantly increases (p＜0.01), is about 6 times of normal control group.Compare with model group, HA content all significantly reduces (p＜0.05) in compd A, compd B, compd E, each administration group rat blood serum of compound F 17-hydroxy-corticosterone; Hyp content all extremely significantly reduces (p＜0.01), is about 2～2.5 times of normal control group.
Table 3 The compounds of this invention to tetracol phenixin cause the rat chronic liver injury influence (X ± S, n=10)
Compare with the normal control group:
##P＜0.01; Compare with model group:
*P＜0.01,
*P＜0.01.
(3) influence that hepatic tissue pathology is changed: rats in normal control group hepatic tissue structural integrity is clear, the liver lobule rule, and the liver cell form is arranged normal, radial distribution around central passages through which vital energy circulates.The bridge type necrotic extent is wide and involve a plurality of leaflets and be how little leaf necrosis in the model group rats'liver leaflet, and fiber is separated to form the disorder of companion's leaflet structure, formation early stage liver cirrhosis or liver cirrhosis, and serious wen appears in most rats.Hepatocellular degeneration in compd A, compd B, compd E, each administration group rats'liver leaflet of compound F 17-hydroxy-corticosterone, appearance necrosis, minority is with the bridge type necrosis, and part liver tissues of rats portal area is slightly chip necrosis on every side, hepatocellular degeneration in the leaflet, point, the necrosis of kitchen range shape, as seen fibrosis around the acidophilic body, portal area, fiber is separated to form, but leaflet structure keeps, the part liver tissues of rats is accompanied the leaflet structure disorder for separating, and does not have liver cirrhosis, does not see wen.
Conclusion: this experiment is with CCl
4Cause chronic hepatic injury, the model group liver tissues of rats is early stage liver cirrhosis or liver cirrhosis, and most rats form serious wen.And wen appears in none example of The compounds of this invention treatment group rat, and the prompting The compounds of this invention has the sex change of very strong lipotropism fat, prevents the effect of hepatic necrosis.Experiment shows that The compounds of this invention can make liver tissue injury significantly alleviate, and then is reflected as ALT on biochemical, the AST vigor reduces, and Hyp content reduces.
HA is the practical index of reflection hepatocyte function and hepatic fibrosis process, and its rising amplitude and hepatic fibrosis change over positive correlation.Model group rat blood serum HA content significantly raises, and The compounds of this invention all can suppress the rising of serum HA, shows that The compounds of this invention has the liver function of improvement, alleviates the effect of hepatic fibrosis.
In sum, The compounds of this invention has significant anti hepatic fibrosis, and chronic hepatic injury is had remarkable therapeutic action.
The activity of the anti-HIV of experimental example 4 The compounds of this invention
Trial-product: physiological saline: commercial;
Compd A capsule: 150mg;
Compd B capsule: 150mg;
Compd E capsule: 150mg;
Compound F 17-hydroxy-corticosterone capsule: 150mg.
Experimental technique: mouse is divided into each administration group at random by body weight, 15 every group.Fasting was prohibited water 14 hours before the administration, and compd A, B, E, F are diluted to desired concn gastric infusion 20ml/kg by 300mg/kg with physiological saline.Pluck eyeball respectively at different time after the administration and get blood (each time is got 5 of blood), separation of serum, 4 ℃ of preservations are cultivated in cell after the inactivation treatment and are measured its inhibition HIV-1 activity.Add the cell culture fluid, 2 * 10 that contains 5% mice serum in the 96 porocyte culture plates simultaneously
5MT cell and the 100TCID of cell/ml
50HIV-1 IIIB virus liquid, every kind of concentration repeats 2 holes; Establish virus control hole and blank hole simultaneously.Put 37 ℃, 5%CO
2With cultivate in the saturated humidity incubator, every day the observation of cell pathology.Cultivate 4 days (96 hours) back and inhale cell culture supernatant, cell dyes with MTT; Supernatant liquor is after suitably releasing, measure HIV-1P24 antigen by the operation steps that HIV-1P24 antigen-agent test kit provides, compare to medicine group and negative control group, calculate pastille serum the antigenic inhibiting rate of HIV-1P24 (inhibiting rate %=(negative control group OD-is to medicine group OD)/(negative control group OD-blank group OD) * 100%).
Experimental result: in MT-4 cell cultures 96 hours, each is organized administration mice serum (final concentration is 5%) and is not seen that causing cell virus becomes.Behind the gastric infusion, mice serum is cultivated the effect that suppresses HIV-1 IIIB and is seen Table 4 in the MT-4 cell.Behind mouse administration compd A, B, E or the F, 5% serum is cultivated in the MT-4 cell has significant inhibitory effect to HIV-1 IIIB P24 antigen, after the administration during 45min inhibiting rate be about 75% near 90% during 80min, be higher than 50% during 240min.
5% serum is cultivated the antigenic inhibiting rate to HIV-1 IIIB P24 after the administration of table 4 mouse in the MT-4 cell
Conclusion: anti-HIV-1 effect result of study shows in the body, and behind the gastric infusion, 5% mice serum is to people's T lymphocyte MT-4 cell free of toxic effects that goes down to posterity; After the administration in 4 hours 5% mice serum in the MT-4 cell, cultivate HIV-1 had restraining effect significantly, and the time length is longer.Show that The compounds of this invention has the activity of significant anti-HIV, and less to the toxicity of human body.
4, embodiment
The embodiment of form is described in further detail foregoing of the present invention by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following examples.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.The auxiliary material of each formulation can be replaced with acceptable accessories in following examples, perhaps reduces, increases.
Replace 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-11-oxo-18 β with compd A in following examples, 20 β-volatile oil-12-olefin(e) acid ester, compd B replaces 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester, compd E replaces 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester, compound F 17-hydroxy-corticosterone replaces 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester.
Embodiment 1 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-11-oxo-18 β, the preparation of 20 β-volatile oil-12-alkene enzyme ester
Step 1: 13.5g (100mmo1) VITAMIN B4 is dropped in the reaction flask, add 100ml95% ethanol and 8g sodium hydroxide then, stirring and dissolving, slowly drip 20g (160mmol) ethylene bromohyrin, stirring at room reaction 10h, decompression and solvent recovery, residuum are with the 90ml chloroform: methyl alcohol (1: 2) heating for dissolving, cross and filter out insolubles, decolorizing with activated carbon, filtrate add the 90ml chloroform again, freezing crystallization, get 9-(1-hydroxyethyl-2-yl) VITAMIN B4 15.3g, yield: 85.3%.
Step 2: in the dry reaction bottle, add the 100ml acetonitrile, 9.4g (20mmol) 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid, add 10ml Dimethylamino pyridine (DMAP) then, after the stirring and dissolving, add 10g dicyclohexylcarbodiimide (DCC), be warming up to 40 ℃, stir 10min, slowly add 9-(1-hydroxyethyl-2-yl) VITAMIN B4 4.5g (25mmol) then, dropwise continuous stirring reaction 20h, cross the dicyclohexylurea (DCU) that filters out generation, reclaim solvent, residuum extracts with ethyl acetate 50ml * 3 after adding an amount of frozen water, the organic layer drying, reclaim solvent, the dehydrated alcohol recrystallization gets 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester 5.7g, yield: 45.1%.
Ultimate analysis (C
37H
53N
5O
4): C:70.06%, H:8.62%, N:11.01% (theory: C:70.33%, H:8.45%, N:11.08%).
Embodiment 2 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-11-oxo-18 β, the preparation of 20 β-volatile oil-12-olefin(e) acid ester
Step 1: 13.5g (100mmol) VITAMIN B4 is dropped in the reaction flask, add 100ml95% ethanol and 8g sodium hydroxide then, stirring and dissolving.Slowly drip 22g (160mmol) 2-bromopropyl alcohol, be warming up to 35 ℃ of stirring reaction 15h, decompression and solvent recovery, residuum is with the 90ml chloroform: methyl alcohol (1: 2) heating for dissolving, and cross and filter out insolubles, decolorizing with activated carbon, filtrate adds the 100ml chloroform again, freezing crystallization gets 9-(1-hydroxypropyl-2-yl) VITAMIN B4 14.9g, yield: 77.2%.
Step 2: with reference to step 1 among the embodiment 1,9-(1-hydroxyethyl-2-yl) VITAMIN B4 is replaced with 9-(1-hydroxypropyl-2-yl) VITAMIN B4, get 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid ester 6.1g, yield: 47.3%.
Ultimate analysis (C
38H
55N
5O
4): C:70.57%, H:8.69%, N:10.76% (theory: C:70.66%, H:8.58%, N:10.84%).
Embodiment 3 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-18 β, the preparation of 20 β-volatile oil-12-olefin(e) acid ester
Step 1: with reference to step 1 among the embodiment 1.
Step 2: with reference to step 2 among the embodiment 1, with 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid replaces with 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid, get 2-(VITAMIN B4-9-yl) ethyl 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester 5.4g, yield: 43.2%.
Ultimate analysis (C
37H
55N
5O
3): C:70.06%, H:8.62%, N:11.01% (theory: C:71.92%, H:8.97%, N:11.33%).
Embodiment 4 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-18 β, the preparation of 20 β-volatile oil-12-olefin(e) acid ester
Step 1: with reference to step 1 among the embodiment 2.
Step 2: with reference to step 2 among the embodiment 1,9-(1-hydroxyethyl-2-yl) VITAMIN B4 is replaced with 9-(1-hydroxypropyl-2-yl) VITAMIN B4, with 3 beta-hydroxies-11-oxo-18 β, 20 β-volatile oil-12-olefin(e) acid replaces with 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid, get 2-(VITAMIN B4-9-yl) propyl group 3 beta-hydroxies-18 β, 20 β-volatile oil-12-olefin(e) acid ester 5.6g, yield: 48.1%.
Ultimate analysis (C
38H
57N
5O
3): C:72.15%, H:9.12%, N:11.05% (theory: C:72.23%, H:9.09%, N:11.08%).
The preparation of embodiment 5 The compounds of this invention sheets
1, prescription:
Prescription 1:
Compd A, B, E or F 6g
Microcrystalline Cellulose 50g
Pregelatinized Starch 100g
10%PVP K30 ethanol liquid is an amount of
Magnesium Stearate 3g
Prepare 1000 altogether
Prescription 2:
Compd A, B, E or F 13g
Microcrystalline Cellulose 50g
Pregelatinized Starch 100g
10%PVP K30 ethanol liquid is an amount of
Magnesium Stearate 3g
Prepare 1000 altogether
Prescription 3:
Compd A, B, E or F 150g
Microcrystalline Cellulose 80g
Pregelatinized Starch 150g
10%PVP K30 ethanol liquid is an amount of
Magnesium Stearate 3g
Prepare 1000 altogether
2, preparation technology:
It is standby that raw material and auxiliary material separated pulverizing are crossed 80 mesh sieves; Granulation solution preparation: getting PVP K30, to add concentration be that 30～95% medicinal alcohols are made 5～10% solution; Get raw material and auxiliary materials and mixing, add granulation solution and make softwood in right amount, 20 orders are granulated, and after 50～70 ℃ of dryings, the whole grain of 18 orders adds the Magnesium Stearate mixing; Measure granule content, compressing tablet, detection lug is heavy at random; Finished product is examined entirely, the packing warehouse-in.
The capsular preparation of embodiment 6 The compounds of this invention
1, prescription:
Prescription 1:
Compd A, B, E or F 13g
Microcrystalline Cellulose 50g
Pregelatinized Starch 100g
10%PVP K30 ethanol liquid is an amount of
Magnesium Stearate 3g
Prepare 1000 altogether
Prescription 2:
Compd A, B, E or F 110g
Microcrystalline Cellulose 50g
Pregelatinized Starch 100g
10%PVP K30 ethanol liquid is an amount of
Magnesium Stearate 3g
Prepare 1000 altogether
Prescription 3:
Compd A, B, E or F 150g
Microcrystalline Cellulose 80g
Pregelatinized Starch 150g
10%PVP K30 ethanol liquid is an amount of
Magnesium Stearate 3g
Prepare 1000 altogether
2, preparation technology:
It is standby that raw material and auxiliary material separated pulverizing are crossed 80 mesh sieves; Granulation solution preparation: getting PVP K30, to add concentration be that 30～95% medicinal alcohols are made 5～10% solution; Get raw material and auxiliary materials and mixing, add granulation solution and make softwood in right amount, 20 orders are granulated, and after 50～70 ℃ of dryings, the whole grain of 18 orders adds the Magnesium Stearate mixing; Measure granule content, capsule is filled, with the machine testing loading amount; Finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 7 The compounds of this invention particulate
1, prescription:
Prescription 1:
Compd A, B, E or F 13g
Icing Sugar 1000g
The 2%HPMC50% ethanolic soln is an amount of
Prepare 1000 bags altogether
Prescription 2:
Compd A, B, E or F 55g
Icing Sugar 1000g
The 2%HPMC50% alcoholic solution is an amount of
Prepare 1000 bags altogether
Prescription 3:
Compd A, B, E or F 110g
Icing Sugar 900g
The 2%HPMC50% ethanolic soln is an amount of
Prepare 1000 bags altogether
Prescription 4:
Compd A, B, E or F 300g
Icing Sugar 1700g
The 2%HPMC50% ethanolic soln is an amount of
Prepare 1000 bags altogether
2, concrete steps:
Raw material and auxiliary material were pulverized 100 mesh sieves, standby; Take by weighing raw material and auxiliary material according to recipe quantity, the method that raw material and Icing Sugar are progressively increased with equivalent mixes, and it is an amount of to add the 2%HPMC50% ethanolic soln, stirs, and makes suitable softwood, crosses 20 mesh sieves and granulates, and the whole grain of 18 mesh sieves is crossed in 60 ℃ of oven dry; Sampling, the content of main ingredient is determined loading amount, packing in the work in-process chemical examination particle; Finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 8 The compounds of this invention liquid drugs injections
1, prescription:
Prescription 1:
Compd A, B, E or F 13g
Polysorbate 80 10g
Water for injection 2000ml
Prepare 1000 altogether
Prescription 2:
Compd A, B, E or F 37g
Polysorbate 80 20g
Water for injection 2000ml
Prepare 1000 altogether
Prescription 3:
Compd A, B, E or F 110g
Polysorbate 80 50g
Water for injection 5000ml
Prepare 1000 altogether
Prescription 4:
Compd A, B, E or F 300g
Polysorbate 80 100g
Water for injection 10000ml
Prepare 1000 altogether
2, preparation technology:
To produce with the ampoule dosing with vessel, plant and instrument etc. clear up, degerming, depyrogenation; Take by weighing raw material and auxiliary material by prescription, get the water for injection that Polysorbate 80 adds dosing amount 80%, stirring and dissolving; The needle-use activated carbon that adds dosing amount 0.05% stirs 15min, filters, and takes off charcoal, adds raw material in solution, and stirring and dissolving is measured the also pH value of regulator solution, and benefit adds to the full amount of water for injection, constant volume; Soup is checked clarity, the inspection of semifinished product through the smart filter of the millipore filtration of 0.22 μ m; Soup is loaded in the ampoule 100 ℃ of flowing steam sterilization 30min, leak detection, lamp inspection; Finished product is examined entirely, the packing warehouse-in.
Claims (9)
1. the compound that is shown below or its steric isomer:
Wherein,
X is
Y is guanine-9-base, VITAMIN B4-9-base, 2,6-diaminopurine-9-base, 2-aminopurine-9-base or its 1-denitrification is assorted, the 3-denitrification is assorted or the 8-aza analogues perhaps removes aza analogues for cytosine(Cyt)-1-base, uridylic-1-base, thymus pyrimidine-1-base or its 3-;
R
1Be H, F, Cl, Br or I;
R
2Be H, perhaps 1～3 molecule glucose base, glucal acidic group, arabopyranose base, arbinofuranose base, rhamanopyranosyl, ribosyl, deoxyribosyl, lactose base, galactosyl, galacturonic acidic group, malt-base, mannose group, xylosyl;
R
3, R
4, R
5Independently hydroxyl, perhaps replacement or unsubstituted C respectively do for oneself
1-6Alkyl, thiazolinyl or the alkane hydroxyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, methylol, hydroxyethyl, hydroxypropyl, hydroxyl butyl; Wherein, described substituting group is selected from hydroxyl, amino, nitro, halogen, C
1-6The alkyl or alkenyl of straight or branched, C
6-10Aryl, C
1-4The alkyl amido of straight or branched, C
1-4The alkoxy carbonyl of straight or branched;
R
6Replace or unsubstituted C
1-6The alkyl or alkenyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl, 1-pentenyl, pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, methylol, hydroxyethyl, hydroxypropyl, hydroxyl butyl; Wherein, described substituting group is selected from hydroxyl, amino, nitro, halogen, C
1-4The alkyl or alkenyl of straight or branched.
2. compound as claimed in claim 1 or its steric isomer, wherein,
X is
Y is guanine-9-base, VITAMIN B4-9-base, 2,6-diaminopurine-9-base, 2-aminopurine-9-base, cytosine(Cyt)-1-base, uridylic-1-base or thymus pyrimidine-1-base;
R
1Be H, F, Cl or Br;
R
2Be H, perhaps 1～3 molecule glucose base, glucal acidic group, arabopyranose base, arbinofuranose base, rhamanopyranosyl;
R
3, R
4, R
5Independently hydroxyl, perhaps replacement or unsubstituted C respectively do for oneself
1-4Alkyl, thiazolinyl or the alkane hydroxyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl, methylol, hydroxyethyl, hydroxypropyl, hydroxyl butyl;
R
6For replacing or unsubstituted C
1-4The alkyl or alkenyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, 1-butylene base, crotyl, 3-butenyl, isobutenyl.
3. compound as claimed in claim 2 or its steric isomer, wherein,
X is
Y is guanine-9-base, VITAMIN B4-9-base, cytosine(Cyt)-1-base, uridylic-1-base or thymus pyrimidine-1-base;
R
1Be H, F or Cl;
R
2Be H, perhaps 1～3 molecule glucose base, glucal acidic group, arabopyranose base, arbinofuranose base;
R
3, R
4, R
5Independently hydroxyl, perhaps replacement or unsubstituted C respectively do for oneself
1-3Alkyl, thiazolinyl or the alkane hydroxyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, vinyl, 1-propenyl, 2-propenyl, different propenyl, methylol, hydroxyethyl, hydroxypropyl;
R
6For replacing or unsubstituted C
1-4The alkyl of straight or branched, be selected from methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl.
4. compound as claimed in claim 3 or its steric isomer, wherein,
X is
Y is guanine-9-base, VITAMIN B4-9-base or cytosine(Cyt)-1-base;
R
1Be H, F or Cl;
R
2Be H ,-β-D-glucosyl group ,-the alpha-D-glucose base or-β-D-glucal acidic group-alpha-D-glucose aldehydic acid base;
R
3Be methyl or methylol;
R
4Be methyl or methylol;
R
5Be methyl, hydroxyl or methylol;
R
6Be methyl, ethyl, propyl group or sec.-propyl.
5. compound as claimed in claim 4 or its steric isomer, wherein,
X is
Y is guanine-9-base;
R
1Be H;
R
2For H or-β-D-glucal acidic group-alpha-D-glucose aldehydic acid base;
R
3Be methyl;
R
4Be methyl;
R
5Be methyl;
R
6Be ethyl or sec.-propyl.
6. the application in the medicine of preparation treatment and/or pre-viral infection as the described arbitrary compound of claim 1～5 or its steric isomer.
7. treat and/or prevent application in the medicine of hepatic diseases as the described arbitrary compound of claim 1～5 or its steric isomer in preparation.
As the described arbitrary compound of claim 1～5 or its steric isomer as the essential activeconstituents and the pharmaceutical composition of pharmaceutically acceptable carrier.
9. pharmaceutical composition as claimed in claim 8 is oral preparations or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100706091A CN101190936A (en) | 2006-12-01 | 2006-12-01 | Compound with antiviral activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100706091A CN101190936A (en) | 2006-12-01 | 2006-12-01 | Compound with antiviral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101190936A true CN101190936A (en) | 2008-06-04 |
Family
ID=39486151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100706091A Pending CN101190936A (en) | 2006-12-01 | 2006-12-01 | Compound with antiviral activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101190936A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102633856A (en) * | 2012-03-31 | 2012-08-15 | 广西师范大学 | Oleanolic acid-pyrimidine conjugate as well as preparation method and application thereof |
| JP2012528801A (en) * | 2009-05-31 | 2012-11-15 | チャンスー チア−タイ ティアンチン ファーマシューティカル カンパニー リミテッド | Method for synthesizing glycyrrhetinic ester derivative and deoxyglycyrrhetinic ester compound |
-
2006
- 2006-12-01 CN CNA2006100706091A patent/CN101190936A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012528801A (en) * | 2009-05-31 | 2012-11-15 | チャンスー チア−タイ ティアンチン ファーマシューティカル カンパニー リミテッド | Method for synthesizing glycyrrhetinic ester derivative and deoxyglycyrrhetinic ester compound |
| CN102633856A (en) * | 2012-03-31 | 2012-08-15 | 广西师范大学 | Oleanolic acid-pyrimidine conjugate as well as preparation method and application thereof |
| CN103864880A (en) * | 2012-03-31 | 2014-06-18 | 广西师范大学 | Oleanolic acid-pyrimidine conjugate as well as preparation method and application thereof |
| CN103864882A (en) * | 2012-03-31 | 2014-06-18 | 广西师范大学 | Oleanolic acid-pyrimidine conjugate as well as preparation method and application thereof |
| CN103864882B (en) * | 2012-03-31 | 2015-10-28 | 广西师范大学 | Oleanolic Acid-miazines conjugate and its preparation method and application |
| CN103864880B (en) * | 2012-03-31 | 2016-01-20 | 广西师范大学 | Oleanolic Acid-miazines conjugate and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5294509B2 (en) | Cycloastragenol monoglucoside, process for its production and use as a pharmaceutical composition | |
| CN104510747B (en) | A kind of new medicine use of iridoid glycoside | |
| JPH03188021A (en) | Drug for combating retrovirus and its preparation | |
| BRPI0108435B1 (en) | formulation and use of low dose entecavir | |
| CN101278928B (en) | Medicament composition containing levocarnitine or its derivatives and use thereof | |
| CN111214463A (en) | Application of resveratrol in preparing anti-SARS-CoV-2 virus medicine | |
| CN100584348C (en) | Anti-hepatitis medical combination | |
| CN101190936A (en) | Compound with antiviral activity | |
| CN101190935B (en) | Compound used for viral infect | |
| CN109988104B (en) | Kaempferol and isonicotinamide eutectic crystal, preparation method, pharmaceutical composition and application thereof | |
| US10729713B2 (en) | Pharmaceutical composition for treating hepatitis, liver fibrosis, and liver cancer | |
| JP3102945B2 (en) | Hepatitis treatment | |
| CN101108224B (en) | Plants natural base extractive and formulated product and use thereof | |
| CN101190937B (en) | Compound with liver-protecting activity | |
| CN115124532B (en) | Rhein and matrine eutectic crystal, preparation method, composition and application thereof | |
| CN115124420B (en) | Rhein and matrine eutectic hydrate, preparation method, composition and application thereof | |
| JP3247381B2 (en) | Anticholeratoxin agent | |
| CN115105519A (en) | Pharmaceutical composition for treating hepatitis B and preparation method thereof | |
| JP3560970B2 (en) | Antimalarial synergistic composition containing benzoflumetol | |
| CN1985988B (en) | Novel medicine composition for treating hepatic diseases | |
| CN113546083B (en) | Pharmaceutical composition for treating pneumonia | |
| CN113546067B (en) | Anthraquinone derivatives with antiviral effect | |
| JPH03271226A (en) | Renal trouble remedying agent | |
| CN1985987B (en) | Medicine composition of glycyrrhizic acid or its salt and reduced glutathione | |
| JP3186365B2 (en) | Liver disease drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Tianchen Avenue in Ji'nan high tech Development Zone in Shandong City, No. 2518, block A Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone in Shandong City, No. 2518, block A Applicant before: Huang Zhenhua |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080604 |